4226 93 Α7 Β7 經濟部中央標準局員工消費合作社印絮 五·、發明説明（ 發明背景 生物産生的自由基圃牽涉多種疾病狀胃胃胃19118 於氣氣琛境下存活牽涉到生物産生自由 醮性化學物種與有機顦控制自由基®痒生的能力間複雜 的交互作用（Del Maestro RF, Acta Phy Scan Suppl· 492:153-68(198〇))e寄主有機體舆生物摩生的自由基 瞎交互作用結果導致联重生物化學改费，最终造成細16 傷寄舆有機體死亡β自由基围反應産物的 量疾病狀態，此等疾病部份來自於胞内自由 高誘發的細胞傷害。此等疾病包含但笄限於癌症，心血 管病，中植神經糸统病症，骨病，老化，阿兹海黙氏费 呆，發炎病症，類風濕性蘭節炎，自讎免疫病，呼吸窘 迫及肺氣腫。 自由基園傷害多種疾病狀態的蘭騙於文獻上有詳细 記載，多種細胞組成份包含酶、離子通遒、結構蛋白質 及膜脂質皆為反應性自由基團物種可能的攻擊目檫（1^〇6-Evans C, Mol Aspects of Hed 13(1): 1-111(1992)) 。於搪當部位之抗氣化狀態可限制细胞傷害。自由基黼 與此等可能目標的反鼴可能損壞某種範園的細胞功能， 結果導致病理變化及最終導致細胞死亡β於可能反應部 位之抗氣化狀態可限制損害。抗氧化薄於保_ DUA、蛋 白質（包含脂蛋白）及膜脂霣對抗氧化傷害扮演要角。 有強力證據提示自由基圃傷害促成多種慢性健康藺暖 的病因。對大部份人類疾病而言，由内生來朦形成的氣 本紙張尺度適用中國國家標準（CNS )八4^ U10X297公鬌） ---------装------1Τ------β (請先閱讀背面之注^^項再填¾.本頁) 經濟部中央標準局員工消費合作社印1i 4 2 2 b ^ j A7 _B7__五、發明説明（> ) 化劑纽發於初步病症之後，但氣化傷寄使原發病變加重 β例如，再灌流傷寄定義為於缺血發作後，器官重新建 立血流造成的傷寄β氣的恢«雖然需要，但會造成受傷 組嫌的氣化劑生成而暫時惡化傷寄（Uraizee Α, Circulation 75(6): 1237-1248(1987))。缺氣心肌於 再氧化時因脂質過氧化反鼴增高對抗氣化劑防衛下降由 G u a n i e r i 報告（B i 〇 c h i β - B i 〇 p h jr s - A C T A 7 1 Μ 2 ) : 1 5 7 - 1 6 4 (1982))。再灌流傷害中，缺血發作後内皮受«部位的 發炎反應由喃中性細胞钴著及活化而産生超氧化物。多 種不同臨床病情中，肝臓産生的氣自由基園也增加》病 毒性肝炎及慢性活動性肝炎中，大量受剌激的巨噬細胞 稹聚於肝臟而産生自由基釀。因肝臓産生的自由基團增 加，大量有毒化學品引起毒性肝傷害，經常僳由細胞色 素Ρ-450媒介。可歸結由鐵立丁（Ferritin)釋放雄催化 羥基基圍生成乃造成多種旰矇疾病的機構（Lee VN，N Eng J of Med; Review P . 1118(1995))〇 氧化及使用抗氣化劑對多種發炎病情的治療相當重要 類風濕性關節炎（RA)傺最常見的慢性發炎病。流行病 學研究顯示典型及特定R A的盛行率為0.3至1.5%。慢性 持纗性發炎的颶節病伴随箸發炎的類風濕闢節炎生成Η2()2β 發炎遇程中，氣自由基圈也産生，待別由多形核白血球 (ΡΜΝ)及巨噬細胞産生。任何慢性或急性發炎病中· 及巨噬細胞可産生02及Η202 β肺结核，乾癖，条統性 红斑性狼瘡，其它自體免疫病及成人呼吸窘迫症候群也 --------.1&------,玎------Λ— (請先閲讀背面之注意事項再填¾本頁) 本紙張尺度適用中國國家椋隼（CNS) A4規格（2IOX297公釐） 42269 經濟部中央標率局員工消费合作社印聚 A7 B7 五、發明説明（4 ) 值得一提為屬於氧化促成的發炎病，另外尚有多棰其它 疾病β 氧基團産生及脂質過氣化反應過程也變成中樞神經条 統（CNS)剌傷及中風（例如觖血）領域研究學者注意 點。許多研究顯著證實於受傷或缺凼的CHS發生自由基 國及脂質過氧化反應（Bal1 ED，J_!ieurotrauaa 9(Suppl U : S165-S172(1992))0 酋經提議抗氧化剤可保護不發生乳癌及其它癌症，包 含腦癌及肝癌，以及保護膜血管病及輅#病（Wiseian B ,Free Radical Res 21(3): 187-94 (1990)。驗證可 保護模式性細胞膜包含核膜不受致癌自由基函中間物及 脂質過氣化産物可能的傷害。動鼸粥瘤硬化造成嚴重併 發症且發生率高使研究學者注意力集中於預防及治療此 種血管病態，可能經由保護飫密度脂蛋白（LDL)不受氣 化傷害（Steinberg D, N Engl J of Hed 14: 915-924 (1989))0 發明說明 根據本發明，提供一種治療或抑制自由基團誘發疾病 狀態之方法，俱經由對有霈要的晡乳類投予抗氣化數量 之17冷-二氫雌馬性素酮或其I碕酸酯之翳藥可接受性 鹽。由該遇程推論本發明提供一種於晡乳類治療自由基 團與梅、離子通道、結構蛋白質及膜脂質反應之方法， 包括投予17/?-二氫雌馬性素颳或其翳_可接受性硖酸 SB鹽做為播牲酶基霣而其投予數置你足夠選擇性與自由 本紙張尺度適用中國國家標準（CNS ) A4規格（2丨OX297公釐） (請先聞靖背面之注意事項再填寫本頁〕 .裝. 訂4226 93 Α7 Β7 Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs, 5. Explanation of the invention (Background of the invention: Free radical gardens produced by living organisms are involved in a variety of diseases. Stomach and stomach) 19118 Surviving in the environment of qi and air is involved in the creation of biological freedom Complex interactions between chemical species and the ability of organic plutonium to control free radicals® itching (Del Maestro RF, Acta Phy Scan Suppl. 492: 153-68 (198〇)) e. Blind interactions between host organisms and biologically induced free radicals The result of the action led to a combination of biochemical changes, and eventually caused a small amount of β-free radical reaction products in the organism. These diseases are partly due to intracellular free high-induced cellular injury. These diseases include However, it is limited to cancer, cardiovascular disease, mesangial system disease, bone disease, aging, Alzheimer's disease, inflammation, rheumatoid arthritis, autoimmune disease, respiratory distress and emphysema The free radical garden hurts various disease states. It is well documented in the literature that a variety of cellular components including enzymes, ion channels, structural proteins and membrane lipids are reactive. Possible attack targets of free radical species (1 ^ 〇6-Evans C, Mol Aspects of Hed 13 (1): 1-111 (1992)). The anti-gasification state at the site can limit cell damage. Freedom The reaction between the basic target and these possible targets may damage the cell function of a certain type of garden, resulting in pathological changes and eventually cell death. The anti-gasification state at the possible reaction site can limit the damage. Antioxidant is thinner than DUA, DUA, Proteins (including lipoproteins) and membrane lipids play an important role in combating oxidative damage. There is strong evidence that free radical garden injuries contribute to a variety of chronic healthy warming causes. For most human diseases, they are formed endogenously. The size of the paper is applicable to the Chinese National Standard (CNS) 8 4 ^ U10X297 male) --------- installation ----- 1T ------ β (Please read the note on the back first ^ ^ Refill this page ¾. This page) Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs, 1i 4 2 2 b ^ j A7 _B7__ V. Description of the invention (>) The chemical agent was released after the initial illness, but the gasification injury was sent Aggravating the primary disease β For example, reperfusion injury is defined as the reestablishment of blood by the organ after an ischemic attack Β caused injury to send gas recovery << although required, but will cause the gasification agent generates injured group suspected of worsening injury temporarily sent (Uraizee Α, Circulation 75 (6): 1237-1248 (1987)). Myocardial deprivation of myocardium due to lipid peroxidation increases during anti-oxidation due to lipid peroxidation, and the defense against gasification agents decreases (B i 〇chi β-B i 〇ph jr s-ACTA 7 1 Μ 2): 1 5 7-1 6 4 (1982)). In the reperfusion injury, the inflammatory response of the endothelium after the ischemic attack is caused by the activation and activation of cobalt in neutrophils to produce superoxide. In a variety of different clinical conditions, the amount of qi free radicals produced by the liver is also increased. In viral hepatitis and chronic active hepatitis, a large number of stimulated macrophages gather in the liver to produce free radicals. Due to the increase of free radicals generated by liver crickets, a large number of toxic chemicals cause toxic liver injury, often mediated by cytochrome P-450. It can be attributed to the release of ferritin to catalyze the formation of hydroxyl groups and cause a variety of obstructive diseases (Lee VN, N Eng J of Med; Review P. 1118 (1995)). Oxidation and use of anti-gasification agents Rheumatoid arthritis (RA), the most common chronic inflammatory disease, is important for the treatment of multiple inflammatory conditions. Epidemiological studies have shown that the prevalence of typical and specific R A is 0.3 to 1.5%. Chronic persistent inflammation of Hurricane Disease is accompanied by inflammation of rheumatoid arthritis. 2 () 2β In the course of inflammation, the air radical circle is also generated. It is to be produced by polymorphonuclear leukocytes (PMN) and macrophages. . In any chronic or acute inflammation, and macrophages can produce 02 and Η202 β tuberculosis, dry addiction, systemic lupus erythematosus, other autoimmune diseases and adult respiratory distress syndrome --------. 1 & ------, 玎 ------ Λ— (Please read the notes on the back before filling this page ¾) This paper size applies to China National Standard (CNS) A4 (2IOX297 mm) 42269 Printed A7 B7, Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the Invention (4) It is worth mentioning that it is an inflammation disease caused by oxidation. In addition, there are many other diseases. Β-oxygen generation and lipid over-gasification reaction The process has also become the focus of researchers in the field of central nervous system (CNS) stinging and stroke (such as bleeding). Many studies have significantly confirmed that free radicals and lipid peroxidation occur in injured or deficient CHS (Bal1 ED, J_! Ieurotrauaa 9 (Suppl U: S165-S172 (1992)). Breast cancer and other cancers, including brain and liver cancer, and protective membrane vascular disease and rickets (Wiseian B, Free Radical Res 21 (3): 187-94 (1990). Validated to protect model cell membranes including nuclear membranes from Possible damages of carcinogenic free radical intermediates and lipid over-gasification products. Acute atherosclerosis causes severe complications with a high incidence, leading researchers to focus on the prevention and treatment of this vascular disease, possibly through the protection of radon-density lipids Protein (LDL) is not damaged by gasification (Steinberg D, N Engl J of Hed 14: 915-924 (1989)). Description of the invention According to the present invention, a method for treating or inhibiting a disease state induced by a free radical group is provided. An essential anti-evaporation milk is administered with an anti-evaporation amount of 17 cold-dihydroestrogensone or its hydrazone acceptable salt. It is inferred from the process that the present invention provides an anti-evaporation therapy Free radicals and plums, Method for sub-channel, structural protein and membrane lipid reaction, including administration of 17 /?-Dihydroestrogen scrape or its _acceptable saccharic acid SB salt as a sowing enzyme base, and its administration is sufficient for you Optional and free This paper size applies the Chinese National Standard (CNS) A4 specification (2 丨 OX297 mm) (please listen to the precautions on the back of Jing before filling this page).
經濟部中央標率局員工消費合作社印製 五、發明説明（4 ) 基圍反應並抑制自由基園與病人的_、離子通道、結構 蛋白質或暌脂質反窸的數量》抗氧化_治療待別有效的 病情為癌症•中樞神經条統病症•骨病，老化，周邊血 管病，類風濕性醑節炎，自醱免疫病，呼吸窘迫，肺氣 腫，預防再灌流傷害•病毒性肝炎，慢性活動性肝炎， 肺結核，乾»,糸统性红斑性狼瘡，成人呼吸窘迫症候 群，中樞神經条統創傷及中風β 用於本發明，治療一詞涵蓋治療既有病情，改善病情 或提供緩解病情；而抑制一詞包含抑制或預防病情的進 行或發展β 17彡-二氫《馬性素阑-3-硫酸醣之醫第可接受性鹽包 含但非僅限於齡金屬邇，驗土金靥鹽，铵鹽，含1-6侮 碩原子之烷基胺鹽或各籲烷基含1-6雇碩原子之二烷基 胺鹽。 17彡-二fi雌馬性素醜之抗氧化性質偁於標準藥理試 驗程序建立，該_理試驗程序你藉TBARS(硫巴比妥酸反 醮性物質方法）分析自由醛（Yagi K.，Biochei Ned 15: 212-21M1976)测鼉17/?-二篦雌馬性素醑抑制曇露於 Cu+ +離子或培餐内皮细胞誘發生成氣化改質低密度脂 蛋白（LDL)的能力（Parthasarathy S， Proc Natl Acad Sci USA 86: 1046-1050(1989))〇 此種標準第理試驗程序所得結果驗證17彡-二氫雌馬 性素篇乃LDL氣化之強力抑制劑，可抑制氣化過程高逹 100%。豬主動蘼内皮細胞媒介氣化檢定分析獲得ICso ™ 6 - (請先閱讀背面之注意事項再填¾本頁) -裝_ '^ -泉 本紙張尺度適用中*»；家榡車{ CNS ) A4C格（210'〆297公釐） 經濟部中央標準局員工消費合作社印裝 42269a A7 B7五、發明説明（r ) 為0.315；uM。供比較用，本試驗程序之雌酮獲得ICso為 0 . 5 6 ju Μ 0 基於此等試驗程序所得結果，17jS-二氫_馬性素爾 及其硫酸_之B藥可接受性鹽，例如鹼金屬鹽，鹸土金 颶鹽，銨馥，含1-6雇碩原子之烷基胺鹽或各艏烷基含 1-6個碩原子之二烷基胺鹽可用做抗氣化劑，用於治療 或抑制自由基團誘發疾病狀態。 本發明之抗氣化劑可淨或與翳槃載劑配方供投藥，配 方比例偽由化合物溶解度及化學性質，選用的投藥途徑 及標準藥理實務決定。醫藥載劑可為固體或液體。 固體載劑包含一種或多種物質也可做為矯味劑，潤滑 劑，增溶劑，懸浮劑，填充劑，滑動劑，壓缩助劑，黏 结劑，或錠劑-崩散劑；也可做為包膠材料《散劑中， 載爾為細分固體其與細分活性成份混合β錠劑中，活性 成份輿具有所需壓编性質的載劑以適當比例混合並壓縮 成所需形狀及大小。散劑及錠劑較佳含高達99%活性成 份。適當固體載劑包含例如磷酸鈣，硬脂酸鎂，滑石， 糖類，乳糖，糊精，澱粉，明，纖維素，甲基纖維素 (請先閱讀背面之注意事項再填落本頁) 子漿藥 Β _ 離糖醱或Β 及 ，於物當 蠟劑浮合適 黏液懸混它 熔乳或之其 低，解者有 ， _ 溶二含 啶液可，劑 咯浮份劑載 毗 懸成溶饅 基 ，性機液· 31 劑活有。7 乙液。，類 > 聚溶物水肪 , 備成如脂 納製組劑或 素於醚載頚 維用加體油 潘。劑及液性 基脂載劑性受 甲樹體酏受接 羧換液，接可 ，交 劑可第 本紙張尺度適用中國國家標準（CNS ) Α4規格（2丨0X297公釐） ^226 S ά ΑΊ Β7 經濟部中央標準局貝工消費合作社印製 五、發明説明（ b ) 1 1 添 加 劑 例 如 增 溶 劑 > 乳 化 劑 1 緩 衝 劑 • 保 藏 劑 9 甜 味 劑 1 1 > 矯 味 劑 t 懸 浮 劑 > 增 稠 劑 7 色 料 黏 度 調 節 劑 9 安 定 1 I 劑 或 滲 透 壓 調 節 劑 0 經 □ 及 腸 外 投 藥 用 之 液 體 載 劑 之 適 請 1 | 例 包 含 水 (部份含前述添加劑例如纖雒素衍生物， 較佳 -先 閲 讀 1 1 羧 甲 基 纖 維 素 納 鹽 溶 液 )， 醇類（包 含 一 元 醇 及 多 元 醇 如 背 ιέ 1 | 之 1 二 醇 類 )及其衍生物， 卵磷脂類及油類（例 如 分 皤 椰 子 油 注 意 1 I 及 花 生 油 )0 供睹外投藥， 載劑亦可為油性酯如油酸乙 事 項 1 [ 再 \ I 酯 及 油 酸 異 丙 61 0 無 菌 液 體 載 劑 可 用 於 無 菌 液 體 劑 型 紐 填 寫 本 1 成 物 供 賎 外 投 藥 加 壓 紐 成 物 之 液 體 載 劑 可 為 鹵 化 烴 或 頁 1 1 其 它 翳 藥 可 接 受 性 推 進 劑 0 1 1 無 菌 溶 液 劑 或 懸 浮 液 劑 等 液 體 η 藥 組 成 物 可 供 例 如 肌 1 1 肉 腹 内 或 皮 下 注 射 用 〇 無 菌 溶 液 劑 也 可 經 靜 眤 投 藥 0 1 1 訂 1 本 發 明 化 合 物 也 可 呈 液 醱 或 固 體 組 成 物 劑 型 經 口 投 藥 〇 本 發 明 之 抗 氣 化 劑 可 以 習 知 拴 劑 形 式 經 直 腸 投 藥 ΰ 藉 1 赛 内 或 支 氣 管 内 吸 入 或 吹 入 投 藥 用 Ϊ 本 發 明 之 抗 氧 化 劑 1 1 可 配 方 成 水 溶 液 或 部 份 水 溶 液 » 然 後 成 氣 霧 m 型 式 使 用 1 1 〇 本 發 明 化 合 物 可 經 皮 投 藥 i % 使 用 經 皮 阽 布 内 含 活 性 咸 I 化 合 物 及 載 劑 9 該 載 劑 對 活 性 化 合 物 呈 惰 性 » 對 皮 無 1 1 毒 且 可 使 活 性 劑 經 由 皮 » 輪 送 供 % 統 性 吸 收 入 血 流 0 載 1 I 劑 可 里 任 一 種 形 式 例 如 乳 音 劑 及 軟 音 劑 1 糊 精 ί m 漿 劑 ! | 及 封 阻 裝 置 〇 乳 膏 劑 及 軟 蕾 剤 可 為 油 / 水 或 水 / 油 型 黏 1 1 稠 液 體 或 半 固 體 乳 液 〇 糊 劑 包 括 可 吸 收 粉 '末 分 散 於 石 m 1 | 或 含 活 性 成 份 之 親 水 石 蟠 也 適 用 0 多 種 封 阻 裝 置 可 用 於 1 I 將 活 性 成 份 釋 放 入 血 流 例 如 8 内 含 活 性 成 份 含 或 未 含 載 薄（之 1 1 1 t 1 本紙張尺度適用中國國家標準（CNS ) Α4規格（2IOX2W公嫠） 42264226 Π3 Α7 Β7 五、發明説明（9 ) 貯器上方覆蓋半透膜，或内含活性成份之基體。其它封 劑 媒 性 受 接 可 藥 0 與 由 經 可 劑 〇 化 知氣 已抗 獻之 文明 考發 參本 由， 置外 裝此 阻 有 含 成 方 配 % 5 乳 劑 液 溶 之 物 合 化 性 活 % 2 佳 較 情 病 的 在 存 徑 途 藥 投 。物 部成 患組 菌定 真特 予用 投使 可隨 劑求 洗裔 或量 劑剤 膏 理徹 藥02 準0. 標為 於量 基劑 0 曰 #每 改物 體合 固化 定性 待活 的期 療預 治， 受果 接結 及得 -所 度序 程程 重驗 嚴試 佳最 最下 物況 合情 化種 於該 低到 以逹 常至 通量 療劑 治高 。增 克後 千隨/ 。 克始 撤開 ο 量 5 _ - 齊 克小 千之 /量 克劑 確定 正決 的驗 藥經 投的 内人 管病 氣療 支治 或受 奏接 經別 、各 外對 陽於 、基 口生 經醫 ;方 止處 為由 果將 效量 佳劑 如 例 型 劑 位 單 呈 傷可 物物 成成 ττΗ Ηη 链绍 蕖 ， 醫型 佳劑 較等 。此 活裝 量封 適如 含例 成物 分成 再組 裝 封 為 可 型 劑 位 單 於量安 。劑 ， 劑位劑 囊簞瓶 _ 的小 或份 ， 劑成 _ 錠性散 (請先閱請背面之注意事項再填寫本頁) 裝 丁 -3 劑 劑 式 瓿囊形 器 射 注 充 填 先 預 袋 藥 瞜 asp 液 含 膠 為 可 如 例 型 劑 身 本 劑 錠 或 包 封 之 物 成 組 等 此 之 量 數 當 適 為 成 經濟部中央梂準局員工消费合作社印製 本紙張尺度適用中國國家標準{ CNS ) A4規格< 210X297公釐）Printed by the Employees' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (4) The number of _, ion channels, structural proteins or anti-lipid reaction of radicals and the free radical garden and patients. Effective conditions are cancer • Central nervous system disorders • Bone disease, aging, peripheral vascular disease, rheumatoid arthritis, autoimmune disease, respiratory distress, emphysema, prevention of reperfusion injury • viral hepatitis, chronic Active hepatitis, tuberculosis, stem », systemic lupus erythematosus, adult respiratory distress syndrome, central nervous system trauma and stroke β For the purposes of the present invention, the term treatment encompasses the treatment of an existing condition, improves the condition or provides remission; And the word inhibition includes inhibiting or preventing the progress or development of the disease. Β 17 彡 -dihydro 《Maldidin-3-sulfose medically acceptable salts include, but are not limited to, age metal hafnium, soil test gold hafnium salt, ammonium Salts, alkylamine salts containing 1-6 atoms, or dialkylamine salts containing 1-6 atoms in each alkyl group. The anti-oxidant properties of 17 雌 -di-fi equine sex hormones were established based on standard pharmacological test procedures. You can analyze free aldehydes (Yagi K., Biochei Ned) using TBARS 15: 212-21M1976) Measured 17 /?-Estradiolin inhibits exposure to Cu + + ions or cultivates endothelial cells to induce gasification and modification of low density lipoprotein (LDL) (Parthasarathy S, Proc Natl Acad Sci USA 86: 1046-1050 (1989)). The results of this standard first-principle test procedure verify that 17 二 -dihydroestrogen is a powerful inhibitor of LDL gasification and can inhibit the gasification process by up to 100%. ICso ™ 6 obtained from pig gastrointestinal endothelial cell media gasification assay analysis-(Please read the precautions on the back before filling this page) -Packing _ '^ -Spring paper size is applicable * »; Furniture car {CNS) A4C grid (210'〆297 mm) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 42269a A7 B7 V. Description of the invention (r) is 0.315; uM. For comparison, the ICso of estrone obtained in this test procedure is 0.5 6 ju Μ 0. Based on the results obtained from these test procedures, 17jS-dihydro-malezol and its sulfuric acid B drug acceptable salts, such as alkali metals Salts, arsenic salts, ammonium sulfonium salts, alkylamine salts containing 1 to 6 atoms, or dialkylamine salts containing 1 to 6 atoms in each alkyl group can be used as anti-gasification agents for Treat or inhibit free radicals to induce disease states. The anti-gasification agent of the present invention can be used for drug administration either net or with a carrier formulation, and the formulation ratio is pseudo-determined by the solubility of the compound and chemical properties, the selected administration route and standard pharmacological practice. Pharmaceutical carriers can be solid or liquid. Solid carriers containing one or more substances can also be used as flavoring agents, lubricants, solubilizers, suspending agents, fillers, sliding agents, compression aids, binders, or lozenge-disintegrating agents; also as encapsulation In the powder, the carrier is a finely divided solid, which is mixed with the finely divided active ingredient. In the β lozenge, the active ingredient and the carrier having the required compression properties are mixed in an appropriate ratio and compressed into a desired shape and size. Powders and lozenges preferably contain up to 99% active ingredients. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, starch, cellulose, methyl cellulose (please read the precautions on the back before filling out this page) Drug B _ from glycocalyx or B and, when the wax is floating, suitable viscous suspension of its molten milk or its low, the solution is, _ dissolving dipyridine-containing solution is possible, the agent is suspended and dissolved into a solvent馒 Base, sex machine fluid · 31 agents live. 7 Liquid B. , ≫ Poly-solubility water fats, prepared as a fat-receiving agent or a fat-reinforced body oil supplemented with ether. Agent and liquid base lipid carrier, accept the formazanite, accept carboxyl for liquid exchange, accept, and deliver. The paper size is subject to Chinese National Standard (CNS) Α4 specification (2 丨 0X297 mm) ^ 226 S ά ΑΊ Β7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (b) 1 1 Additives such as solubilizers > Emulsifiers 1 Buffers • Preservatives 9 Sweeteners 1 1 > Flavoring agents t Suspensions & gt Thickener 7 Colorant viscosity regulator 9 Stabilizer 1 I agent or osmotic pressure regulator 0 Suitable for liquid carriers for parenteral administration via □ and parenteral 1 | Examples include water (part of which contains the aforementioned additives such as cellulose Derivatives, preferably-first read 1 1 Carboxymethylcellulose sodium salt solution), alcohols (including monohydric alcohols and polyhydric alcohols such as diols 1 | 1 diols) and their derivatives, lecithins and oils (Such as tillering coconut oil Note 1 I and peanut oil) 0 For external use, the carrier can also be an oily ester such as ethyl oleate 1 [ Re \ I esters and isopropyl oleate 61 0 Sterile liquid carriers can be used for sterile liquid dosage forms. Fill in this 1 product for external administration. The liquid carrier for pressurized products can be a halogenated hydrocarbon or page 1 1 Other peony Acceptable propellants 0 1 1 Liquid η pharmaceutical compositions such as sterile solutions or suspensions can be used, for example, for intramuscular or subcutaneous injection. 1 Sterile solutions can also be administered by static administration. 0 1 1 Order 1 The compound of the invention can also be administered orally in the form of a liquid or solid composition. The anti-gasification agent of the present invention can be administered rectally in the form of a conventional suppository. Antioxidant 1 1 can be formulated as an aqueous solution or part of an aqueous solution »and then used as an aerosol m-type 1 1 〇 The compound of the present invention can be administered transdermally i% I Compounds and Carriers 9 This carrier is inert to the active compound »non-toxic to the skin 1 1 and allows the active agent to be delivered via the skin» Round-the-clock absorption into the bloodstream 0 Load 1 I can be in any form such as Emulsifiers and softeners 1 Dextrin m m Slurry! | And blocking device 0 Creams and soft buds can be oil / water or water / oil type 1 1 thick liquid or semi-solid emulsions 0 pastes include The absorbable powder is dispersed in the stone m 1 | or the hydrophilic stone ballast containing active ingredients is also applicable. 0 A variety of blocking devices can be used. 1 I release the active ingredients into the blood stream. For example, 8 contains active ingredients with or without thin film ( No. 1 1 1 t 1 This paper size applies to Chinese National Standard (CNS) A4 specification (2IOX2W male) 42264226 Π3 Α7 Β7 V. Description of the invention (9) The top of the container is covered with a semi-permeable membrane, or a substrate containing active ingredients. Other encapsulants can receive the medicine 0 and the civilized test of the civilized medicine that has been resisted by the chemical agent 0. The external composition of this solution has a compound content of 5% emulsion solution. Live% 2 is better than insidious drug delivery. The adult group of the affected part of the organism is determined to use the medicine, which can be washed with the dosage or the amount of the lotion, the cream, and the medicine. 02 quasi 0. Marked as the amount of the base agent 0. ## Each modified object is solidified and qualitatively waits for the period of life. Therapy pretreatment, fruit binding, and re-examination of the sequence of procedures, retesting, rigorous test, the best condition, and the best condition are reasonable, from low to normal treatment with high-flux therapeutic agents. Thousands after adding grams. Keshi withdrawal ο amount 5 _-Qi Ke Xiaoqianzhi / gram gram dose to determine the correct test drug after the internal tube disease gas therapy treatment or acceptance of the menstruation, each outside to the Yang, Jikou Health and medicine; Fang Zhishui is the result of the effect of a good amount of good agents such as the example of a single dosage form can be wounded into ττΗ Ηη chain Shao 蕖, better medical type agent. This live-pack volume seal is suitable to be divided into cases and repacked into a remodelable package. Small, or small parts of the capsules, capsules, tablets, tablets, tablets, tablets, tablets (please read the precautions on the back before filling this page) Filling D-3 capsules The bag medicine 瞜 asp solution contains glue, which can be used as an example, the dosage form, the tablets, or the packaged materials, etc. The amount should be suitable for printing. This paper is suitable for use in China. Standard {CNS) A4 size < 210X297 mm)